iRhythm Holdings, Inc. filings document the public-company reporting of a digital health care business centered on ambulatory cardiac monitoring. Recent Form 8-K disclosures report operating results, financial condition, guidance-related exhibits, Regulation FD materials, material agreements, executive compensation policy changes, board appointments, and changes in the independent registered public accounting firm.
Proxy materials cover director elections, board and committee structure, executive compensation, equity awards, and stockholder voting matters. The filing record also documents the completed holding-company reorganization under which iRhythm Holdings became successor registrant to iRhythm Technologies, including common-stock continuity and predecessor registration-termination records.
iRhythm Holdings President and CEO Quentin S. Blackford reported a performance-based stock vesting and related tax sale. On February 24, he acquired 46,687 shares of common stock at no cost through the vesting of performance RSUs granted on February 27, 2023, after the board committee determined the performance conditions were met.
On February 25, he sold 25,540 shares of common stock at an average price of $135.4189 per share solely to cover tax withholding and remittance obligations tied to that vesting. After these transactions, he directly owned 186,126 shares of iRhythm common stock.
iRhythm Holdings, Inc. Chief Accounting Officer Marc Wade Rosenbaum reported an open-market sale of 280 shares of common stock at an average price of $140.91 per share on February 24, 2026. After this sale, he directly holds 10,601 shares of iRhythm common stock.
The transaction was executed under a pre-arranged Rule 10b5-1 trading plan that he established on May 12, 2025 and modified on November 25, 2025, which is designed to allow systematic share sales according to preset instructions.
iRhythm Holdings, Inc. executive vice president of strategic business operations Mervin Smith reported an open-market sale of common stock. On February 24, 2026, he sold 732 shares at an average price of $140.91 per share.
After this transaction, Smith directly owned 15,106 shares of iRhythm common stock. The sale was executed under a pre-established Rule 10b5-1 trading plan that Smith adopted on November 19, 2025, indicating the trades were made according to a predetermined schedule.
iRhythm Holdings, Inc. director Abhijit Y. Talwalkar reported exercising employee stock options for 5,312 shares at $10.710 per share and receiving an equal number of common shares on February 23, 2026. He then sold 5,312 common shares in multiple open-market transactions at prices including $143.400, $145.317, $146.951, and $147.616 per share, leaving 20,299 shares of common stock held directly.
All transactions were carried out under a Rule 10b5-1 trading plan established on May 12, 2025. The exercised option was originally granted on May 23, 2016 for 21,248 shares, vested in thirty-six equal monthly installments, and has an expiration date of May 23, 2026; the plan covers options expiring in 2026 and 2027.
iRhythm Holdings, Inc. files its annual report describing a specialized cardiac monitoring business built around its Zio wearable patch and ZEUS analytics software. The company delivers long-term continuous and mobile cardiac telemetry monitoring services mainly through Medicare-enrolled diagnostic testing facilities.
iRhythm highlights more than twelve million patient reports and nearly three billion hours of curated heartbeat data, a workforce of about 2,400 employees, and a market value of roughly $4.9 billion. The report emphasizes dependence on reimbursement, complex billing and regulatory oversight, strong competition, and expanding use of AI-driven diagnostics and international growth.
iRhythm Holdings reported strong growth for the fourth quarter and full year 2025. Fourth quarter revenue reached $208.9 million, up 27.1% from 2024, with gross margin at 70.9%. The company delivered net income of $5.6 million, its first quarter of positive GAAP net income.
For full year 2025, revenue rose 26.2% to $747.1 million, and gross margin improved to 70.6%. The annual GAAP net loss narrowed to $44.6 million from $113.3 million, and free cash flow was positive at $34.5 million, the first positive year in company history. Unrestricted cash, cash equivalents and marketable securities were $583.8 million at December 31, 2025.
For 2026, iRhythm guides to revenue of $870–$880 million and an adjusted EBITDA margin of 11.5%–12.5%, reflecting expectations for continued volume-led growth, margin expansion, and operating leverage.
Sands Capital Management, LLC and Frank M. Sands report beneficial ownership of 1,699,645 shares of iRhythm Holdings, Inc. common stock, representing 5.3% of the outstanding class. This percentage is based on 32,219,143 shares outstanding as of October 23, 2025, as disclosed in iRhythm’s Form 10-Q.
The shares are held in accounts of various Sands Capital clients, including institutions and individuals, and no single client holds more than 5% of the class. The filers state the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of iRhythm.